Skip To Main Content
Contact us
|
Help
Home
About
ADR
ADR Archives
Resources
Contact
Flash e-reader
Choose a chapter:
Introduction
Kidney
Pancreas
Liver
Intestine
Heart
Lung
Deceased Organ Donation
Allocation Policies
Appendix
Table Selection
Choose an organ:
All Organs
Kidney
Pancreas
Kidney/Pancreas
Heart
Lung
Heart/Lung
Intestine
Liver
Choose a group:
Choose a characteristic:
Requires
Adobe Acrobat Reader
Table 7.8
Adjusted Graft Survival, Pancreas After Kidney (PAK) Transplants
Survival at 3 Months, 1 Year, 5 Years, and 10 Years
3 Months
1 Year
5 Years
10 Years
(Tx 2007 - 2008)
(Tx 2007 - 2008)
(Tx 2003 - 2008)
(Tx 1998 - 2008)
N
%
Std. Err.
N
%
Std. Err.
N
%
Std. Err.
N
%
Std. Err.
Total
All
467
87.0%
1.6%
467
80.5%
1.8%
1,864
55.6%
1.4%
3,215
37.3%
1.5%
Transplant Center State
Alabama
9
78.0%
12.9%
9
55.8%
15.3%
29
71.8%
8.3%
31
69.7%
8.3%
Arkansas
0
-
-
0
-
-
1
0.0%
0.0%
3
32.1%
20.0%
Arizona
17
94.2%
5.5%
17
88.3%
7.5%
53
62.6%
8.7%
66
48.1%
10.1%
California
36
97.2%
2.7%
36
83.2%
6.2%
125
49.1%
6.0%
195
14.1%
8.3%
Colorado
2
+
+
2
+
+
7
72.4%
15.3%
12
39.4%
16.1%
Connecticut
1
+
+
1
+
+
13
17.8%
9.6%
37
33.1%
8.6%
District of Columbia
1
+
+
1
+
+
16
58.1%
13.9%
34
0.0%
0.0%
Florida
4
74.5%
18.9%
4
74.5%
18.9%
33
57.8%
8.9%
78
51.4%
6.2%
Georgia
1
+
+
1
+
+
14
40.4%
12.9%
28
32.1%
11.0%
Hawaii
0
-
-
0
-
-
1
0.0%
0.0%
3
0.0%
0.0%
Iowa
1
+
+
1
+
+
6
84.0%
13.5%
15
35.4%
14.6%
Illinois
28
89.4%
5.7%
28
89.4%
5.7%
81
72.0%
5.3%
124
38.9%
9.0%
Indiana
24
95.9%
3.9%
24
95.9%
3.9%
71
72.5%
6.9%
77
72.2%
6.4%
Kansas
4
75.6%
18.3%
4
75.6%
18.3%
10
57.3%
15.5%
19
28.3%
15.8%
Kentucky
4
75.6%
18.2%
4
75.6%
18.2%
11
27.8%
14.5%
19
0.0%
0.0%
Louisiana
4
49.0%
21.4%
4
23.7%
15.8%
22
70.3%
10.4%
49
34.4%
11.9%
Massachusetts
14
93.3%
6.3%
14
93.3%
6.3%
91
59.1%
5.9%
138
41.3%
6.7%
Maryland
10
90.0%
8.9%
10
78.9%
12.5%
69
59.1%
6.8%
180
43.4%
5.3%
Maine
3
+
+
3
+
+
17
44.2%
14.7%
19
46.5%
13.4%
Michigan
10
60.6%
14.4%
10
40.5%
14.2%
58
36.2%
6.9%
101
30.8%
5.9%
Minnesota
52
92.0%
3.8%
52
86.0%
4.9%
248
47.4%
3.7%
622
35.3%
2.5%
Missouri
2
+
+
2
+
+
13
76.1%
11.5%
13
76.3%
11.4%
North Carolina
8
100.0%
0.0%
8
87.5%
11.0%
50
54.9%
8.1%
85
53.7%
6.7%
North Dakota
2
0.0%
0.0%
2
0.0%
0.0%
20
54.0%
10.8%
32
57.7%
9.7%
Nebraska
16
+
+
16
+
+
30
66.0%
11.8%
52
46.8%
12.4%
New Hampshire
7
71.2%
15.7%
7
71.2%
15.7%
13
84.4%
9.7%
13
84.5%
9.7%
New Jersey
11
81.4%
11.2%
11
62.6%
14.0%
63
45.1%
6.6%
85
37.0%
8.1%
Nevada
0
-
-
0
-
-
0
-
-
1
+
+
New York
33
81.4%
6.7%
33
71.5%
8.0%
87
59.2%
6.5%
136
38.9%
6.1%
Ohio
35
97.2%
2.7%
35
97.2%
2.7%
132
70.7%
4.9%
201
49.3%
5.2%
Oklahoma
2
100.0%
0.0%
2
46.3%
26.0%
8
36.3%
15.3%
9
32.3%
14.0%
Oregon
0
-
-
0
-
-
10
60.7%
14.3%
15
50.0%
13.4%
Pennsylvania
31
90.4%
5.1%
31
77.5%
7.3%
107
56.9%
5.6%
171
28.5%
6.5%
Rhode Island
6
83.6%
13.6%
6
83.6%
13.6%
22
67.5%
9.9%
24
70.4%
9.2%
South Carolina
5
60.8%
19.1%
5
60.8%
19.1%
19
27.1%
11.0%
36
23.9%
9.1%
South Dakota
6
83.6%
13.6%
6
83.6%
13.6%
24
53.3%
11.2%
24
52.8%
11.2%
Tennessee
6
83.7%
13.5%
6
83.7%
13.5%
38
54.0%
8.9%
67
47.0%
7.3%
Texas
30
73.7%
7.8%
30
63.3%
8.7%
73
49.4%
6.6%
114
37.2%
6.9%
Utah
3
+
+
3
+
+
32
33.1%
9.3%
41
40.3%
8.2%
Virginia
18
73.4%
10.0%
18
73.4%
10.0%
57
69.8%
6.4%
73
0.0%
0.0%
Vermont
0
-
-
0
-
-
3
66.6%
22.3%
4
74.3%
19.2%
Washington
9
76.6%
13.7%
9
65.2%
15.3%
21
31.9%
15.0%
41
23.6%
13.0%
Wisconsin
12
84.4%
9.8%
12
84.4%
9.8%
66
61.4%
6.2%
128
41.7%
5.9%
Source: OPTN/SRTR Data as of October 1, 2010.
(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.
Cohorts are transplants performed during the years listed at the top of the table.
Graft survival follows individual transplants until graft failure.
Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.
Center volume = Center's yearly transplants performed during the base period, based on pancreas and kidney-pancreas transplants.
Multi-organ transplants are excluded.
Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.